Literature DB >> 23314185

The role of the intestinal microbiota in type 1 diabetes.

Naoko Hara1, Aimon K Alkanani, Diana Ir, Charles E Robertson, Brandie D Wagner, Daniel N Frank, Danny Zipris.   

Abstract

The digestive tract hosts trillions of bacteria that interact with the immune system and can influence the balance between pro-inflammatory and regulatory immune responses. Recent studies suggest that alterations in the composition of the intestinal microbiota may be linked with the development of type 1 diabetes (T1D). Data from the biobreeding diabetes prone (BBDP) and the LEW1.WR1 models of T1D support the hypothesis that intestinal bacteria may be involved in early disease mechanisms. The data indicate that cross-talk between the gut microbiota and the innate immune system may be involved in islet destruction. Whether a causal link between intestinal microbiota and T1D exists, the identity of the bacteria and the mechanism whereby they promote the disease remain to be examined. A better understanding of the interplay between microbes and innate immune pathways in early disease stages holds promise for the design of immune interventions and disease prevention in genetically susceptible individuals.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23314185     DOI: 10.1016/j.clim.2012.12.001

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  27 in total

1.  Explicet: graphical user interface software for metadata-driven management, analysis and visualization of microbiome data.

Authors:  Charles E Robertson; J Kirk Harris; Brandie D Wagner; David Granger; Kathy Browne; Beth Tatem; Leah M Feazel; Kristin Park; Norman R Pace; Daniel N Frank
Journal:  Bioinformatics       Date:  2013-09-10       Impact factor: 6.937

Review 2.  The intestinal microbiota: its role in health and disease.

Authors:  Luc Biedermann; Gerhard Rogler
Journal:  Eur J Pediatr       Date:  2015-01-07       Impact factor: 3.183

Review 3.  Intestinal barrier and gut microbiota: Shaping our immune responses throughout life.

Authors:  Tatiana Takiishi; Camila Ideli Morales Fenero; Niels Olsen Saraiva Câmara
Journal:  Tissue Barriers       Date:  2017-09-28

Review 4.  Adiponectin in inflammatory and immune-mediated diseases.

Authors:  Giamila Fantuzzi
Journal:  Cytokine       Date:  2013-07-11       Impact factor: 3.861

Review 5.  Intestinal dysbiosis and probiotic applications in autoimmune diseases.

Authors:  Gislane Lelis Vilela de Oliveira; Aline Zazeri Leite; Bruna Stevanato Higuchi; Marina Ignácio Gonzaga; Vânia Sammartino Mariano
Journal:  Immunology       Date:  2017-06-29       Impact factor: 7.397

Review 6.  Does the microbiota play a role in the pathogenesis of autoimmune diseases?

Authors:  Mairi H McLean; Dario Dieguez; Lindsey M Miller; Howard A Young
Journal:  Gut       Date:  2014-11-21       Impact factor: 23.059

Review 7.  Influence of host immunoregulatory genes, ER stress and gut microbiota on the shared pathogenesis of inflammatory bowel disease and Type 1 diabetes.

Authors:  Altin Gjymishka; Roxana M Coman; Todd M Brusko; Sarah C Glover
Journal:  Immunotherapy       Date:  2013-12       Impact factor: 4.196

8.  Maternal Antibiotic Treatment Protects Offspring from Diabetes Development in Nonobese Diabetic Mice by Generation of Tolerogenic APCs.

Authors:  Youjia Hu; Jian Peng; Ningwen Tai; Changyun Hu; Xiaojun Zhang; F Susan Wong; Li Wen
Journal:  J Immunol       Date:  2015-09-23       Impact factor: 5.422

9.  Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes.

Authors:  Naoko Hara; Aimon K Alkanani; Charles A Dinarello; Danny Zipris
Journal:  J Mol Med (Berl)       Date:  2013-08-28       Impact factor: 4.599

10.  Reduced morbidity at diagnosis and improved glycemic control in children previously enrolled in DiPiS follow-up.

Authors:  Markus Lundgren; Åsa Sahlin; Camilla Svensson; Annelie Carlsson; Elisabeth Cedervall; Björn Jönsson; Ida Jönsson; Karin Larsson; Åke Lernmark; Jan Neiderud; Tore Vigård; Helena Elding Larsson
Journal:  Pediatr Diabetes       Date:  2014-05-13       Impact factor: 4.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.